

## NEWS RELEASE

**HYDERABAD, INDIA (10 February' 2021)** - Suvan Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter and nine months ended 31 December' 2020. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 10 February' 2021 at Hyderabad.

### Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Period ended		Year ended
	31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
Revenue	2,797.76	2,377.45	1,835.94	7,614.93	6,618.03	8,519.07
EBITDA	1,429.98	988.50	844.59	3,596.95	3,203.03	4,029.10
EBITDA Margin	51.11%	41.58%	46.00%	47.24%	48.40%	47.30%
EBIT	1,342.41	913.50	789.48	3,363.74	3,037.60	3,794.03
EBIT Margin	47.98%	38.42%	43.00%	44.17%	45.90%	44.54%
Finance costs	27.32	32.63	71.76	92.01	146.09	218.13
Depreciation	87.58	75.00	55.11	233.21	165.43	235.07
Taxes	338.75	227.57	197.74	829.79	723.11	875.10
Taxes to PBT	25.76%	25.83%	27.55%	25.36%	25.01%	24.47%
PAT (Standalone)	976.35	653.30	519.99	2,441.95	2,168.40	2,700.80
PAT Margin (Standalone)	34.90%	27.48%	28.32%	32.07%	32.76%	31.70%
Associate Company	160.00	87.53	63.56	350.70	272.44	482.13
PAT (Consolidated)	1,136.25	740.79	579.10	2,792.26	2,428.19	3,170.02
PAT Margin (Consolidated)	40.61%	31.16%	31.54%	36.67%	36.69%	37.21%
EPS (Standalore)	3.84	2.57	2.04	9.59	8.52	10.61
EPS (Consolidated)	4.46	2.91	2.27	10.97	9.54	12.45
Paid up share capital (Re.1/sh)	254.56	254.56	127.28	254.56	127.28	127.28

### Growth Ratios

	Quarter ended 31 Dec 20 to Quarter ended 30 Sep 20	Quarter ended 31 Dec 20 to Quarter ended 31 Dec 19	Period ended 31 Dec 20 to Period ended 31 Dec 19
Growth in income	17.68%	52.39%	15.06%
Growth in EBIDTA	44.66%	69.31%	12.30%
Growth in EBIT	46.95%	70.04%	10.74%
Growth in PAT Standalone	49.45%	87.76%	12.62%
Growth in PAT Consolidated	53.38%	96.21%	14.99%

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
- The Board has declared an Interim Dividend of Re.1.00 per share 100% of face value of Rs.1.00 each.

## Suvan Pharmaceuticals Limited

3. The Board has allotted the Bonus shares at 1:1 ratio in its Board meeting held on 29 September' 2020. Accordingly, the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated.
4. The COVID-19 did not have major impact on the business and research operations, which includes our subsidiary, Suven Pharma, Inc.

**For more information, please visit: <http://www.suvenpharm.com>**

**Risk Statement:**

*Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Pharmaceuticals Limited**